On November 15, 2023, the US Food and Drug Administration (FDA) announced the approval of repotrectinib to treat patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
Repotrectinib is part of a class of drugs called tyrosine kinase inhibitors, or TKIs, which have been beneficial for many patients with oncogene-driven lung cancers. TKIs are a type of therapy that specifically targets changes in genes that are known to promote tumor growth.
Repotrectinib is the third TKI drug for ROS1-positive NSCLC but is the first to be used for patients who either have been previously treated with a different ROS1-directed TKI or have never been treated with a TKI drug.
For more details, including common side effects, please see the FDA press release.
You can find additional information about repotrectinib in the newsfeed on this website.